GHRH Analogs Billing and Prior-Authorization Playbook

What Are GHRH Analogs and Why Does Billing Matter?

GHRH analogs are synthetic peptides that bind the GHRH receptor on anterior pituitary somatotrophs, triggering pulsatile release of endogenous growth hormone. Unlike exogenous recombinant GH (somatropin), these agents preserve the hypothalamic-pituitary feedback loop and produce a more physiologic GH secretion pattern [1]. That pharmacologic distinction creates a billing problem: payers built their coverage frameworks around recombinant GH, and most formularies have no clean slot for a secretagogue.

Key Agents in the Class

Three GHRH analogs appear most often in clinical practice. Sermorelin acetate (GHRH 1-29) received FDA approval in 1997 for diagnostic evaluation and treatment of GH deficiency in children, but the branded product (Geref) was voluntarily withdrawn from market in 2008 for commercial reasons, not safety signals [2]. Tesamorelin, a modified GHRH(1-44) analog, holds active FDA approval exclusively for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [3]. CJC-1295, a synthetic GHRH analog with a drug affinity complex (DAC) that extends its half-life to approximately 6 to 8 days, has never received FDA approval and is available only through compounding pharmacies or research suppliers.

The Coverage Gap

Because sermorelin lacks an active NDA holder and CJC-1295 has no FDA approval at all, neither drug appears on standard commercial formularies. Tesamorelin is the exception. Gilead (formerly Theratechnologies) maintains an active NDA and runs a dedicated patient support program (Egrifta Connect) that handles benefits verification and prior-auth submission [4]. Prescribers working with compounded sermorelin or CJC-1295 should expect out-of-pocket payment models in nearly every scenario.

Billing Codes and Claim Submission

Correct coding is the single largest determinant of whether a GHRH analog claim survives initial adjudication. A miscoded claim triggers an automatic denial before any clinical reviewer sees it.

HCPCS and CPT Codes

Tesamorelin has an assigned HCPCS code: J3490 (unclassified drugs) at many payers, though some regional Medicare Administrative Contractors (MACs) accept J3590 for unclassified biologics. The Endocrine Society's 2011 clinical practice guideline on GH deficiency in adults recommends provocative GH stimulation testing before initiating any GH-axis therapy [5]. The stimulation test itself bills under CPT 80428 (growth hormone stimulation panel) or, if an insulin tolerance test (ITT) is used, CPT 80434 (combined anterior pituitary panel). Arginine-GHRH testing bills as CPT 80428 plus the separate drug administration code (96372 for subcutaneous injection).

Pharmacy Benefit vs. Medical Benefit

Self-administered subcutaneous GHRH analogs typically adjudicate under the pharmacy benefit using NDC numbers. Tesamorelin (Egrifta SV) NDC 68727-600-01 processes through specialty pharmacy channels. Compounded sermorelin does not carry a standard NDC; compounding pharmacies assign in-house NDCs that rarely map to payer adjudication tables. When a payer rejects a pharmacy claim for compounded sermorelin, some clinics re-route the claim through the medical benefit using J3490 with modifier JW (drug amount discarded/not administered), though success rates for this workaround remain low.

Place-of-Service Considerations

Office-administered injections (place of service 11) give prescribers the option of billing under the medical benefit with a buy-and-bill model. This approach works best for tesamorelin in an infectious disease or endocrinology practice where the drug is purchased at 340B pricing. The average sales price (ASP) plus 6% reimbursement under Medicare Part B applies only if the MAC recognizes the HCPCS code. For non-340B practices, the negative margin on buy-and-bill for a drug with a WAC above $50,000 per year makes this model impractical.

Prior-Authorization Requirements by Payer Type

Every major payer category treats GHRH analogs differently. Knowing the payer's framework before submitting saves weeks of back-and-forth.

Commercial Plans

Large commercial insurers (UnitedHealthcare, Aetna, Cigna, Anthem) maintain specific medical policies for "growth hormone and growth hormone-releasing agents." UnitedHealthcare's policy (2024.0243) requires all of the following for coverage of any GH-axis therapy in adults: (a) biochemically confirmed GHD via at least one provocative test showing peak GH <5 mcg/L, (b) clinical signs or symptoms attributable to GHD, (c) MRI of the sella turcica within the prior 12 months, and (d) documented failure or contraindication to recombinant somatropin [6]. Aetna's Clinical Policy Bulletin 0170 mirrors these criteria but sets the GH cutoff at <3 mcg/L for the insulin tolerance test specifically.

Tesamorelin falls under a separate HIV-lipodystrophy policy at most commercial plans. Required documentation includes: confirmed HIV diagnosis, evidence of excess truncal fat (waist circumference or CT-measured visceral adipose tissue), and current antiretroviral therapy. Step therapy through diet and exercise counseling is standard.

Medicare

Medicare Part B does not cover self-administered injectable peptides. Medicare Part D plans may cover tesamorelin if the plan's formulary includes it, but prior authorization is universal. The Medicare Coverage Database shows no National Coverage Determination (NCD) for GHRH analogs. Regional MACs handle coverage on a case-by-case basis, and local coverage determinations (LCDs) for growth hormone therapy typically exclude secretagogues by name.

Medicaid

State Medicaid programs vary widely. A 2022 analysis found that only 11 of 50 state Medicaid programs listed tesamorelin on their preferred drug lists [7]. Compounded peptides are categorically excluded from Medicaid reimbursement in 44 states.

Step Therapy and Clinical Documentation Requirements

Payers almost universally require step therapy through recombinant GH before approving a GHRH analog. The clinical logic: if a patient has confirmed GHD, somatropin is first-line per the Endocrine Society guideline [5].

Building the Prior-Auth Packet

A complete prior-authorization submission for a GHRH analog should include six elements:

1. Provocative GH stimulation test results with the specific test used (ITT, glucagon, arginine, macimorelin), peak GH value, and laboratory reference range
2. IGF-1 level (at least one measurement, ideally two separated by 4+ weeks)
3. Pituitary MRI report dated within the past 12 months
4. Documentation of somatropin trial (drug name, dose, duration, reason for discontinuation or contraindication)
5. Clinical notes describing symptoms attributable to GHD: fatigue, decreased lean mass, increased visceral adiposity, reduced bone density, impaired quality of life (QoL-AGHDA score if available)
6. Letter of medical necessity from a board-certified endocrinologist or infectious disease specialist (for tesamorelin)

Macimorelin as a Diagnostic Advantage

The FDA approved macimorelin (Macrilen) in 2017 as an oral diagnostic agent for adult GHD [8]. Macimorelin stimulation testing is simpler than the ITT and carries a sensitivity of 92% and specificity of 96% for GHD diagnosis at the 2.8 mcg/L cutoff, based on the registrational trial (N=157) [8]. Using macimorelin generates a cleaner, more payer-friendly diagnostic report compared to older provocative tests, because the test has a single validated cutoff and standardized protocol. The test itself bills under CPT 80428.

Appeals and Peer-to-Peer Strategy

Initial denials are common. Roughly 50% of first-time prior-authorization requests for GH-axis therapies receive administrative denials, according to a 2021 survey of 312 endocrinology practices conducted by the American Association of Clinical Endocrinology (AACE) [9]. The good news: structured appeals succeed at a high rate.

Level 1: Written Appeal

The first-level appeal should directly address every denial reason code. Payers commonly deny GHRH analog requests under three rationale categories:

• "Not medically necessary": counter with provocative test results, Endocrine Society guideline citations [5], and symptom documentation
• "Formulary alternative available": counter with documentation of somatropin failure, intolerance, or contraindication (e.g., active malignancy history, prior adverse reaction)
• "Off-label use": counter with compendial support from AHFS Drug Information or Micromedex if the indication has published evidence

Include a concise table mapping the patient's clinical data to each payer criterion. Payer medical directors reviewing appeals spend an average of 7 minutes per case. Make the data scannable.

Level 2: Peer-to-Peer Review

If the written appeal fails, request a peer-to-peer (P2P) call with the plan's medical director. Prepare three things for this call: the patient's peak GH value, the reason somatropin failed, and one published reference supporting GHRH analog use for the specific indication. For tesamorelin in HIV-lipodystrophy, cite the TESAMORELIN (TH9507) Study Group trial published in JAMA, which showed tesamorelin 2 mg daily reduced visceral adipose tissue by 15.2% vs. 5.0% placebo at 26 weeks (N=412, P<0.001) [10].

External Review

After exhausting internal appeals, patients in 48 states have the right to an independent external review under the ACA. External reviewers overturn approximately 40% of endocrine-related denials according to aggregate data from state insurance commissioner reports [11].

Compounded GHRH Analogs: Cash-Pay Models and Compliance

The compounding pharmacy route bypasses insurance entirely for sermorelin and CJC-1295. This is the dominant dispensing model in anti-aging, sports medicine, and wellness-focused practices.

503A vs. 503B Compounding

Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding by a licensed pharmacy with a valid prescription. Section 503B permits outsourcing facilities to compound without individual prescriptions, under FDA inspection [12]. For GHRH analogs, 503B facilities offer batch-produced sermorelin and CJC-1295 vials with certificates of analysis (COAs), which provide better consistency than 503A patient-specific preparations.

Typical Cash-Pay Pricing

Compounded sermorelin (lyophilized powder for reconstitution, 15 mg vial) typically ranges from $150 to $350 per vial through 503B outsourcing facilities. A standard adult dose of 200 to 300 mcg subcutaneously at bedtime yields approximately 50 to 75 doses per 15 mg vial, placing the monthly cost at $60 to $120. CJC-1295 (with or without DAC) runs $180 to $400 per 5 mg vial. These costs are HSA/FSA-eligible when prescribed for a diagnosed medical condition (ICD-10 E23.0, hypopituitarism).

FDA Enforcement and the Bulk Drug Substance List

The FDA's current position on GHRH peptides for compounding remains in flux. Sermorelin appeared on the FDA's bulk drug substances list under evaluation for 503B compounding as of 2024. CJC-1295 has not been nominated to or accepted onto this list, placing it in a regulatory gray zone [12]. Prescribers should verify their compounding pharmacy's FDA registration status and confirm that any GHRH analog they dispense appears on either the 503A traditional compounding pathway or the 503B bulk drug substances under evaluation list.

ICD-10 Coding for GHRH Analog Prescriptions

Accurate diagnosis coding directly affects authorization success. Vague codes trigger automated denials.

Primary Diagnosis Codes

| ICD-10 Code | Description | Use Case | |---|---|---| | E23.0 | Hypopituitarism | Adult GHD, confirmed by provocative testing | | E23.1 | Drug-induced hypopituitarism | GHD secondary to prior radiation or surgery | | E89.3 | Postprocedural hypopituitarism | GHD after transsphenoidal surgery | | E88.1 | Lipodystrophy, not elsewhere classified | HIV-associated lipodystrophy (tesamorelin) | | B20 | HIV disease | Required secondary code for tesamorelin |

Codes to Avoid

Do not use R62.52 (short stature) or E34.3 (short stature, not elsewhere classified) for adult GHD claims. These pediatric-oriented codes trigger age-based claim edits that auto-deny for patients over 18. Similarly, avoid Z76.89 ("encounter for other specified circumstances") as the primary code. Payers interpret this as an elective or cosmetic indication.

Specialty Pharmacy and Distribution Logistics

Tesamorelin distributes through a closed specialty pharmacy network. Egrifta SV requires refrigerated shipping (2 to 8°C) and ships with temperature monitors. Gilead's Egrifta Connect program coordinates benefits investigation, prior auth, copay assistance (eligible patients may pay as little as $0 per month with commercial insurance), and adherence support [4].

Hub Services Workflow

The prescriber submits an enrollment form to Egrifta Connect. The hub verifies insurance benefits within 3 to 5 business days, initiates prior auth if needed, and coordinates shipment from a contracted specialty pharmacy (commonly Accredo, CVS Specialty, or Optum). Average time from prescription to first delivery: 14 to 28 days for commercially insured patients, 30 to 45 days when prior auth requires appeal.

Copay Accumulator and Maximizer Programs

An increasing number of commercial plans (estimated at 25 to 30% of employer-sponsored plans as of 2025) use copay accumulator programs that prevent manufacturer copay cards from counting toward the patient's deductible or out-of-pocket maximum. For a drug with a WAC above $50,000 per year, this can expose the patient to the full deductible after the copay card exhausts. Screen for accumulator programs during benefits verification, and if one is in place, explore Gilead's patient assistance program (PAP) for income-qualified patients (household income <500% FPL).

Monitoring, Renewals, and Ongoing Authorization

Most payers require reauthorization every 6 to 12 months for GH-axis therapies. Renewal submissions must include updated IGF-1 levels and clinical response documentation.

Required Monitoring Labs

The Endocrine Society guideline recommends measuring serum IGF-1 every 6 to 12 months during GH-axis therapy, with dose titration targeting an IGF-1 in the age-adjusted upper half of the normal range [5]. Payers frequently require this lab as a condition of reauthorization. Document fasting glucose and HbA1c at baseline and every 6 months, because GH-axis stimulation can worsen insulin resistance. A 2019 meta-analysis of 37 studies (N=2,675) found that GH replacement therapy increased fasting glucose by a mean of 3.4 mg/dL but did not significantly alter HbA1c at 12 months [13].

Documenting Clinical Response

Payers want evidence that the drug is working. Quantifiable endpoints include: change in body composition (DEXA-measured lean mass and visceral fat), lipid panel trends, bone mineral density (if osteopenia was a baseline finding), and patient-reported quality of life scores. The QoL-AGHDA (Quality of Life Assessment of Growth Hormone Deficiency in Adults) questionnaire is the most widely validated instrument and takes under 5 minutes to administer [14].